Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Atherosclerosis IV: Nursing Management

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Berberine Inhibited SASP-Related Inflammation through RXRα/PPARγ/NEDD4 Pathway in Atherosclerosis.

The American journal of Chinese medicine·2025

Same author

Inhibiting endothelial <i>Rhoj</i> blocks profibrotic vascular intussusception and angiocrine factors to sustain lung regeneration.

Science translational medicine·2024

Same author

PGD 2 /DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice.

Hepatology (Baltimore, Md.)·2024

Same author

Vascular Electrical Stimulation with Wireless, Battery-Free, and Fully Implantable Features Reduces Atherosclerotic Plaque Formation Through Sirt1-Mediated Autophagy.

Small (Weinheim an der Bergstrasse, Germany)·2023

Same author

ROS-Dependent Activation of Autophagy through the PI3K/Akt/mTOR Pathway Is Induced by Hydroxysafflor Yellow A-Sonodynamic Therapy in THP-1 Macrophages.

Oxidative medicine and cellular longevity·2017

Same author

[Studies on light catalysis oxidation degradation of Malachite Green by Photo-Fenton reagent].

Guang pu xue yu guang pu fen xi = Guang pu·2007

Search research articles

Related Experiment Video

Updated: Dec 26, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

Galectin-3 Is a Potential Mediator for Atherosclerosis.

Ziyu Gao^1,2, Zhongni Liu², Rui Wang³

¹State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing 100037, China.

Journal of Immunology Research

|March 10, 2020

Summary

Galectin-3 (Gal-3) is an inflammatory factor involved in atherosclerosis, a key cause of cardiovascular diseases. This review explores Gal-3

More Related Videos

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Related Experiment Videos

Last Updated: Dec 26, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Area of Science:

Cardiovascular Biology
Immunology
Molecular Medicine

Background:

Atherosclerosis is a chronic inflammatory arterial disease underlying major cardiovascular diseases like heart attack and stroke.
Inflammation is recognized as a critical factor in atherosclerosis development and progression.

Purpose of the Study:

To review the role of Galectin-3 (Gal-3) in atherosclerosis.
To elucidate the mechanisms by which Gal-3 influences atherosclerotic processes.
To summarize current Gal-3 agonists and antagonists in atherosclerosis research.

Main Methods:

Literature review of studies on Galectin-3 and atherosclerosis.
Analysis of Gal-3's involvement in inflammatory pathways.
Examination of Gal-3's role in lipid metabolism and cellular processes within arteries.

Main Results:

Galectin-3 (Gal-3) acts as a novel inflammatory factor in atherosclerosis.
Gal-3 participates in key processes including intravascular inflammation, lipid uptake, macrophage activation, cell proliferation, and adhesion.
Various Gal-3 modulators have been investigated in preclinical studies.

Conclusions:

Galectin-3 is a significant mediator in the pathogenesis of atherosclerosis.
Targeting Gal-3 presents a potential therapeutic strategy for cardiovascular diseases.
Further research into Gal-3's mechanisms and modulators is warranted.